copper-67-2IT-BAT-Lym-1

Subscribe to Selected New Research on copper-67-2IT-BAT-Lym-1

10 relevant articles (3 outcomes, 5 trials/studies) found for this Bio-Agent

Description: a copper-67 radiopharmaceutical; Lym-1 is murine anti-lymphoma IgG2a antibody

Also Known As:

(67)Cu-(2-iminothiolane)-(6-(p-(bromoacetamido)benzyl)-1,4,8,11-tetra-azacyclotetradecane-N,N',N'',N'''-tetraacetic acid)-Lym-1 conjugate; 67Cu-2IT-BAT-Lym-1

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

copper-67-2IT-BAT-Lym-1: 10

Organic Chemicals: 40

Organometallic Compounds: 5

copper-67-2IT-BAT-Lym-1: 10

Experts

1.	Xiong, C Y: 1 article (06/2001)
2.	Gumerlock, P H: 1 article (06/2001)
3.	Kroger, L A: 1 article (06/2001)
4.	Winthrop, M D: 1 article (06/2001)
5.	Mack, P C: 1 article (06/2001)
6.	DeNardo, S J: 1 article (06/2001)
7.	DeNardo, G L: 1 article (06/2001)
8.	Leshchinsky, T: 1 article (06/2001)
9.	Shi, X B: 1 article (06/2001)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1997 - "In mice treated with 12.4, 14.8, and 18.5 MBq of 67Cu-2IT-BAT-Lym-1, 50% (9 of 18), 42% (5 of 12), and 50% (3 of 6) of tumors achieved remission or cure; 33% of tumors were cured overall; and significant regrowth delay was observed" 12/15/1997 - "The tumor uptake and radiation dose after 67Cu-2IT-BAT-Lym-1 were about two times greater when a single dose of rIL-2 was added: This may be the basis for enhanced therapeutic efficacy" 06/01/2001 - "67Cu-2IT-BAT-Lym-1 RIT induced an overall response rate of 50% with tolerable toxicity, and 29% of the tumors were cured at cumulated tumor radiation doses of about 1800 cGy" 12/15/1997 - "RESULTS: In mice treated with 335 microCi of 67Cu-2IT-BAT-Lym-1 alone, 28% of tumors were cured" 06/01/2001 - "In preclinical and clinical trials, 67Cu-2IT-BAT-Lym-1 has shown an exceptionally long tumor residence time associated with substantial cumulated radiation doses" Get all the results and reference details, order at left...
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/01/1999 - "Encouraged by the results of 131I-Lym-1 therapy trials for patients with B-cell non-Hodgkin's lymphoma (NHL), this phase I/II clinical trial of 67Cu-2IT-BAT-Lym-1 was conducted in an effort to further improve the therapeutic index of Lym-1-based radioimmunotherapy" 12/01/1999 - "A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma." 07/01/1998 - "Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study." 03/01/1999 - "In conclusion, 67Cu-2IT-BAT-Lym-1 given to non-Hodgkin's lymphoma patients in close temporal proximity to 131I-Lym-1 exhibited greater uptake and longer retention in tumor, resulting in higher radiation dose and therapeutic index than 131I-Lym-1" 09/01/2000 - "BACKGROUND: Prior clinical trials proved that all histologic grades of chemotherapy-resistant B-cell non-Hodgkin's lymphoma (NHL) could respond to radio-immunotherapy (RIT) with 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1" Get all the results and reference details, order at left...
3.	Lymphoma (Lymphomas) 02/15/1995 - "Trial therapy for lymphoma with the radiolabeled chelate-antibody conjugate 67Cu-2IT-BAT-Lym-1 has been promising" 10/01/1999 - "Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model." 06/01/2001 - "The goal of this study was to examine Raji lymphoma xenografts for induction of apoptosis and modulation of apoptosis-related gene and protein expression in response to 67Cu-2IT-BAT-Lym-1 RIT" 06/01/2001 - "In these therapy-resistant, human lymphoma tumors treated with 67Cu-2IT-BAT-Lym-1, apoptosis was convincingly demonstrated to be a major mechanism for the effectiveness of RIT and occurred by p53-independent mechanisms." 02/01/1999 - "67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma." Get all the results and reference details, order at left...
4.	Burkitt Lymphoma (B-ALL) 01/01/1997 - "Nude mice bearing human Burkitt's lymphoma (Raji) tumors (20-524 mm3) were treated with 12.4, 14.8, 18.5, and 23.3 MBq of 67Cu-2IT-BAT-Lym-1" 12/15/1997 - "Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2." 01/01/1997 - "Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji)." Get all the results and reference details, order at left...
4 Diseases and 10 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Interleukin-2 (IL2)
2 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Radioimmunotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Immunotherapy
4.	Drug Therapy (Chemotherapy)
4 Therapies and Procedures and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>